Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Anti-interleukin-6 receptor monoclonal antibody(Biocad Medical, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Anti-interleukin-6 receptor monoclonal antibody(Biocad Medical, Inc.): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, li
9 min read
Cetirizine Amidine Sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Cetirizine Amidine Sodium: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risk
9 min read
Orvacabtagene Autoleucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Orvacabtagene Autoleucel: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risk
9 min read
Site specific immunomodulator(Qu Biologics, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Site specific immunomodulator(Qu Biologics, Inc.): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, mark
9 min read
TGFβi expanded NK cells(Nationwide Children's Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
TGFβi expanded NK cells(Nationwide Children's Hospital): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals,
9 min read
SGB-9768 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
SGB-9768: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
NGM-120 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
NGM-120: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Longxuejie Suppository Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Longxuejie Suppository: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Folinic Acid/Fluorouracil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Folinic Acid/Fluorouracil: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key ris
9 min read
LMY-920 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
LMY-920: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
XH-6003 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
XH-6003: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Yinlan Tiaozhi Capsule Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Yinlan Tiaozhi Capsule: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.